BB Biotech AG (XSWX:BION) Cash Flow from Operations: CHF393.7 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BION BB Biotech AG XSWX:BION
34 GF Score
Price CHF49.55
! 4 Warning Signs
View Full Analysis

What is BB Biotech AG Cash Flow from Operations?

BB Biotech AG XSWX:BION -0.10% 34 Cash Flow from Operations is CHF393.7 Mil as of Mar. 2026. GuruFocus rates XSWX:BION with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2026, BB Biotech AG's Cash Receipts from Operating Activities was CHF1,288.1 Mil. Its Cash Payments was CHF-914.4 Mil. And its Cash Flow from Others was CHF0.0 Mil. In all, BB Biotech AG's Cash Flow from Operations for the three months ended in Mar. 2026 was CHF373.7 Mil.

BB Biotech AG  (XSWX:BION) Cash Flow from Operations Explanation

For financial companies reported in direct method, cash flow from operations contains three items:

1. Cash Receipts from Operating Activities:
Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

BB Biotech AG's cash receipts from operating activities for the three months ended in Mar. 2026 was CHF1,288.1 Mil.

2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.

BB Biotech AG's cash payments for the three months ended in Mar. 2026 was CHF-914.4 Mil.

3. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).

BB Biotech AG's cash flow from others for the three months ended in Mar. 2026 was CHF0.0 Mil.

BB Biotech AG Cash Flow from Operations Related Terms

BB Biotech AG Cash Flow from Operations Historical Data

* Premium members only.

The historical data trend for BB Biotech AG's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG Cash Flow from Operations Chart

BB Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -94.79 231.13 218.28 304.56 309.15

BB Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 289.16 -59.96 63.81 16.14 373.71
XSWX:BION
34GF Score
BB Biotech AG XSWX:BION
Cash Flow from Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BB Biotech AG Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

BB Biotech AG's Cash Flow from Operations for the fiscal year that ended in Dec. 2025 is calculated as:

Cash Flow from Operations(A: Dec. 2025 )
=Cash Receipts from Operating Activities+Cash Payments+Cash Flow from Others
=1359.308+-1050.163+0
=309.1

BB Biotech AG's Cash Flow from Operations for the quarter that ended in Mar. 2026 is:

Cash Flow from Operations(Q: Mar. 2026 )
=Cash Receipts from Operating Activities+Cash Payments+Cash Flow from Others
=1288.079+-914.372+0
=373.7

Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF393.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Operations of CHF393.7 Mil mean?
BB Biotech AG (XSWX:BION) has a Cash Flow from Operations of CHF393.7 Mil as of Mar. 2026. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for BB Biotech AG and its competitors.
Is BB Biotech AG's Cash Flow from Operations too high?
BB Biotech AG's current Cash Flow from Operations is CHF393.7 Mil. Overall, BB Biotech AG has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Cash Flow from Operations compare to VRTX and REGN?
BB Biotech AG's Cash Flow from Operations of CHF393.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for BB Biotech AG and its competitors. BB Biotech AG's current Cash Flow from Operations is CHF393.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Cash Flow from Operations of CHF393.7 Mil. The current Cash Flow from Operations is CHF393.7 Mil. BB Biotech AG's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Cash Flow from Operations is CHF393.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BB Biotech AG Business Description

Address Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
34GF Score

Get the complete analysis for XSWX:BION

Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF49.55
Price